JP2008308430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008308430A5 JP2008308430A5 JP2007156997A JP2007156997A JP2008308430A5 JP 2008308430 A5 JP2008308430 A5 JP 2008308430A5 JP 2007156997 A JP2007156997 A JP 2007156997A JP 2007156997 A JP2007156997 A JP 2007156997A JP 2008308430 A5 JP2008308430 A5 JP 2008308430A5
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- acid
- vivo
- glucuronic acid
- addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 8
- 229940097043 Glucuronic Acid Drugs 0.000 description 6
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 6
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 229950002441 Glucurolactone Drugs 0.000 description 2
- UYUXSRADSPPKRZ-SKNVOMKLSA-N Glucuronolactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 2
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 2
- 229940053049 glucuronolactone Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 210000004127 Vitreous Body Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Description
ヒアルロン酸はＮ−アセチルグルコサミンとグルクロン酸の二糖単位が連結した構造をしており、皮膚、関節液及び眼の硝子体など生体に広く分布し、例えば皮膚においてはハリ及びその弾力性の維持等に、また関節液においては潤滑性の保持等に重要な役割を果たしている。また、ヒアルロン酸は保水性に極めて優れているため化粧品等にも使用され、また、関節炎のための医薬品等としても使用されている。また、健康食品などとしても摂取されている。しかしながらヒアルロン酸は皮膚などから吸収されず、また、経口摂取してもそのままは吸収され難い。また、生体内では、分子量が100万以上の高分子量であると言われている。
そして、ヒアルロン酸の生体内での合成は一定の年齢を過ぎると年齢とともに減少することが知られている。そのため、ヒアルロン酸の生体内での合成を促進することは皮膚の老化防止や関節等の機能維持に非常に重要と考えられ、そのような物質の探索が種々なされている。例えば、生体組織または培養細胞でヒアルロン酸の合成を促進する物質の例としては、Ｎ−アセチルグルコサミン（特開２００１−２５５１）やＮ−アセチルグルコサミン誘導体（特開２００４−５１５７９）が、また、海藻の抽出物（特開平１０−１８２４０２など）が知られている。
一方、ガラクチュロン酸はペクチンの主要構成成分であり、食品添加物等としても使用されているが、ヒアルロン酸生成増強作用は全く知られていない。
また、グルクロン酸は生体内においてグルクロン酸抱合等により、解毒作用を有することが知られており、グルクロン酸またはその塩は医薬品などとして使用されている。また、グルクロン酸の前駆体であるグルクロノラクトンは健康食等として経口摂取されている。しかしながら、グルクロン酸およびその塩またはグルクロノラクトンがヒアルロン酸の生成を促進する作用は知られていない。
And, it is known that the synthesis of hyaluronic acid in vivo decreases with age after a certain age. Therefore, it is considered very important to promote the synthesis of hyaluronic acid in vivo in order to prevent skin aging and maintain the functions of joints and the like, and various searches for such substances have been made. For example, N-acetylglucosamine (Japanese Patent Laid-Open No. 2001-2551) and N-acetylglucosamine derivatives (Japanese Patent Laid-Open No. 2004-51579) are examples of substances that promote the synthesis of hyaluronic acid in living tissue or cultured cells. Extracts (such as JP-A-10-182402) are known.
On the other hand, galacturonic acid is a main component of pectin and is used as a food additive and the like, but hyaluronic acid production enhancing action is not known at all.
In addition, glucuronic acid is known to have a detoxifying action by glucuronic acid conjugation or the like in vivo, and glucuronic acid or a salt thereof is used as a medicine or the like. In addition, glucuronolactone, a precursor of glucuronic acid, is taken orally as a health food and the like. However, it is not known that glucuronic acid and a salt thereof or glucuronolactone promotes the production of hyaluronic acid .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007156997A JP5123574B2 (en) | 2007-06-14 | 2007-06-14 | Hyaluronic acid production enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007156997A JP5123574B2 (en) | 2007-06-14 | 2007-06-14 | Hyaluronic acid production enhancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008308430A JP2008308430A (en) | 2008-12-25 |
| JP2008308430A5 true JP2008308430A5 (en) | 2010-05-13 |
| JP5123574B2 JP5123574B2 (en) | 2013-01-23 |
Family
ID=40236355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007156997A Active JP5123574B2 (en) | 2007-06-14 | 2007-06-14 | Hyaluronic acid production enhancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5123574B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5734578B2 (en) * | 2009-09-03 | 2015-06-17 | ナガセケムテックス株式会社 | Hyaluronic acid extender |
| JP5715434B2 (en) * | 2011-02-15 | 2015-05-07 | 日本水産株式会社 | Hyaluronic acid production enhancer |
| JP7178127B1 (en) | 2021-07-01 | 2022-11-25 | 石福金属興業株式会社 | METHOD FOR MANUFACTURING FUEL CELL ELECTROCATALYST |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005298493A (en) * | 2004-03-19 | 2005-10-27 | Takeda Chem Ind Ltd | Medicinal composition for preventing and/or treating chapped skin |
| ES2255829B1 (en) * | 2004-08-06 | 2007-08-16 | Bioiberica, S.A. | NEW USE OF GLUCOSAMINE SALTS. |
-
2007
- 2007-06-14 JP JP2007156997A patent/JP5123574B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ624749A (en) | A sulfated polysaccharide compound and the preparation and use thereof | |
| EA200802307A1 (en) | BINARY MIXES OF HYALURONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| WO2008090631A1 (en) | Fucoidan-derived oligosaccharide | |
| BR112014014147A2 (en) | cohesive fine liquids for the promotion of safe swallowing in dysphagic patients | |
| BRPI1007325A2 (en) | "Low molecular weight of polysulfated derivatives of hyaluronic acid and drugs containing hyaluronic acid." | |
| ZA200707973B (en) | Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids | |
| RU2015110162A (en) | WATER FOOD COMPOSITION ENRICHED WITH β-GLUCAN | |
| NZ602249A (en) | Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders | |
| MX2009004814A (en) | Nutritional products comprising saccharide oligomers. | |
| HU230385B1 (en) | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, their preparation and use and pharmaceutical compositions containing such derivatives | |
| CY1122198T1 (en) | MEDICAL PRODUCT AND THERAPY | |
| MX2019009711A (en) | Improvements in or relating to organic compounds. | |
| EP2289522B1 (en) | Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer | |
| Zheng et al. | Absorption, metabolism, and functions of hyaluronic acid and its therapeutic prospects in combination with microorganisms: A review | |
| DE60219653D1 (en) | PHARMACEUTICAL COMPOSITION WITH CHITO OLIGOMERS | |
| JP2005507891A5 (en) | ||
| JP2008308430A5 (en) | ||
| Ahsan | The significance of complex polysaccharides in personal care formulations | |
| JP2007126453A5 (en) | ||
| ES2687900T3 (en) | Derivatives of N-desulphated glycosaminoglycans and their use as drugs | |
| Santhosh et al. | Preparation and properties of glucosamine and carboxymethylchitin from shrimp shell | |
| WO2007059874A3 (en) | Compositions for the treatment of osteoarthritis and to nourish the synovial fluid | |
| JP2009096807A (en) | Prophylactic or therapeutic agent for allergic disease | |
| JP5123574B2 (en) | Hyaluronic acid production enhancer | |
| JP2004137183A (en) | Oral administration medicine, health food product or nutritional medicine composition containing glucosaminoglycan or its salt |